What is the target price of SCPH

``` The deep research logic is organized as follows: Okay, let's tackle the user's question about the target price of SCPH. First, I need to check the references provided. The user is asking for the target price, so I should look for any analyst reports or price target data in the references. Looking through the references, I see several mentions of price targets. For example, reference 2 mentions HC Wainwright reaffirming a "buy" rating with a $18.00 price objective. Reference 3 also mentions HC Wainwright's $18.00 target. Then, in reference 9, HC Wainwright again sets a $18.00 target. Reference 10 mentions Leerink Partners with a $12.00 target and TD Cowen with a $25.00 target. Reference 11 and 16 list multiple price targets, including $18 and $12. Reference 15 shows a consensus target of $16.5. I need to compile all these targets. The most recent data is from 2025, so I should focus on those. The user's query is about the current target price, so the latest information is crucial. The references from 2025 (like 9, 10, 11, 16, 15) are the most relevant. HC Wainwright seems to be the most consistent with a $18.00 target, appearing in multiple references. TD Cowen has a higher target at $25.00, and Leerink Partners has a lower one at $12.00. The consensus from reference 15 is $16.5. I should present these findings clearly, highlighting the range and the most recent data. Also, considering the user's interest in technical analysis and short-term investments, mentioning the stock's recent performance and institutional activity might add value. I need to structure the answer with a conclusion first, then detailed analysis, including a table of the latest targets. Make sure to cite the references properly and include the visualization as per the requirements. Also, since the user prefers AR and tech, maybe mention any tech-related aspects of SCPH, but from the references, it's more about pharmaceuticals. So focus on the financial data provided. ``` ### Conclusion 🎯 The target price for **scPharmaceuticals Inc. (SCPH)** ranges between **$12.00 and $25.00** based on recent analyst reports, with a **consensus average of $16.50** as of 2025. The most prominent price target comes from HC Wainwright at **$18.00**, reflecting confidence in the company’s growth trajectory and upcoming product launches. --- ### Detailed Analysis 📊 #### **1. Latest Analyst Price Targets (2025)** Here’s a breakdown of the most recent price targets for SCPH: | Analyst Firm | Price Target | Rating | Key Catalysts | |------------------------|--------------|-------------|--------------------------------------------------------------------------------| | HC Wainwright | $18.00 | Strong Buy | FDA approval for CKD indication, Medicare Part D redesign, and autoinjector launch . | | TD Cowen | $25.00 | Buy | Expanded market potential for Furoscix in CKD and heart failure . | | Leerink Partners | $12.00 | Buy | Near-term profitability expectations post-Q4 2024 results . | | **Consensus Average** | **$16.50** | – | Based on 4 analyst estimates . | #### **2. Key Drivers Behind the Price Targets** - **FDA Approval for CKD**: The recent expansion of Furoscix’s label to treat edema in chronic kidney disease (CKD) patients is a major catalyst. Analysts estimate this could add **$100M+ in annual revenue** by 2025 . - **Medicare Redesign**: Medicare’s 2025 cost-sharing changes are expected to boost demand for Furoscix, reducing out-of-pocket costs for patients . - **Autoinjector Launch**: The SCP-111 Autoinjector (80mg/1mL) could reduce costs by ~70% and improve patient adherence . #### **3. Recent Stock Performance & Institutional Activity** - **Price Action**: SCPH closed at **$5.60** on July 27, 2025, with a 52-week range of **$3.08–$7.37** . - **Institutional Buying**: Rubric Capital Management LP increased its stake by **35.5%** in Q3 2024, and King Luther Capital Management Corp owns **6.12%** of the company . - **Short Interest**: Short interest surged to **26.5%** of shares outstanding in June 2024, indicating high volatility . #### **4. Risks & Challenges** - **High Losses**: SCPH reported a net loss of **$18.8M** in Q4 2024, despite revenue growth . - **Competition**: Generic drug manufacturers like Mylan and Teva could erode Furoscix’s market share . --- ### Final Takeaway 🚨 SCPH’s **$18.00–$25.00 price target range** reflects high upside potential from its CKD expansion and cost-saving innovations. However, investors should monitor execution risks and near-term losses. For a **short to medium-term horizon**, the stock offers **high growth potential** but comes with **significant volatility**.